Cargando…

Role of Osteoprotegerin and Receptor Activator of Nuclear Factor-κB Ligand in Bone Loss Related to Advanced Chronic Obstructive Pulmonary Disease

BACKGROUND: Osteoporosis is a common complication of chronic obstructive pulmonary disease (COPD). Recent clinical and biological researches have increasingly delineated the biomolecular pathways of bone metabolism regulation in COPD. We extended this work by examining the specific association and p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ugay, Ludmila, Kochetkova, Evgenia, Nevzorova, Vera, Maistrovskaia, Yuliya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960959/ https://www.ncbi.nlm.nih.gov/pubmed/27411457 http://dx.doi.org/10.4103/0366-6999.185857

Ejemplares similares

Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss
por: Trouvin, Anne-Priscille, et al.
Publicado: (2010)

Imbalance of osteoprotegerin/receptor activator of nuclear factor-κB ligand and oxidative stress in patients with obstructive sleep apnea-hypopnea syndrome
por: Ma, Xiao-Rong, et al.
Publicado: (2019)

Expression of osteoprotegerin and osteoprotegerin ligand in giant cell tumor of bone and its clinical significance
por: YU, XIUCHUN, et al.
Publicado: (2013)

Osteoprotegerin/receptor activator of nuclear factor-κB ligand are involved in periodontitis-promoted vascular calcification
por: Jiao, Mengyu, et al.
Publicado: (2022)

Platelet-rich fibrin increases the osteoprotegerin/receptor activator of nuclear factor-κB ligand ratio in osteoblasts
por: Sumida, Ryuta, et al.
Publicado: (2019)

Validity of Osteoprotegerin and Receptor Activator of NF-κB Ligand for the Detection of Bone Metastasis in Breast Cancer
por: Elfar, Gamal A., et al.
Publicado: (2017)

Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis.
por: Park, Hye-Rim, et al.
Publicado: (2003)

Soluble receptor activator of nuclear factor κB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients
por: Carmona-Fernandes, Diana, et al.
Publicado: (2011)

Effect of gallium nitrate on the expression of osteoprotegerin and receptor activator of nuclear factor-κB ligand in osteoblasts in vivo and in vitro
por: LI, JINGWU, et al.
Publicado: (2016)

Osteoprotegerin, Soluble Receptor Activator of Nuclear Factor-κB Ligand, and Subclinical Atherosclerosis in Children and Adolescents with Type 1 Diabetes Mellitus
por: Lambrinoudaki, Irene, et al.
Publicado: (2013)

Increase in receptor activator of nuclear factor κB ligand/osteoprotegerin ratio in peri-implant gingiva exposed to Porphyromonas gingivalis lipopolysaccharide
por: Shuto, Takahiro, et al.
Publicado: (2016)

Correlation of plasma osteoprotegerin (OPG) and receptor activator of the nuclear factor κB ligand (RANKL) levels with clinical risk factors in patients with advanced carotid atherosclerosis
por: Giaginis, Constantinos, et al.
Publicado: (2012)

The Role of Osteoprotegerin and Its Ligands in Vascular Function
por: Rochette, Luc, et al.
Publicado: (2019)

Osteoprotegerin protects from generalized bone loss in TNF-transgenic mice
por: Hayer, S, et al.
Publicado: (2003)

Receptor activator of nuclear factor kappa B ligand and osteoprotegerin levels in gingival crevicular fluid
por: Sarlati, Fatemeh, et al.
Publicado: (2012)

The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts
por: Burgess, Teresa L., et al.
Publicado: (1999)

Mycobacterium tuberculosis 10-kDa co-chaperonin regulates the expression levels of receptor activator of nuclear factor-κB ligand and osteoprotegerin in human osteoblasts
por: ZHANG, YUANYU, et al.
Publicado: (2015)

Salivary soluble receptor activator of nuclear factor kappa B ligand/osteoprotegerin ratio in periodontal disease and health
por: Tabari, Zahra Alizadeh, et al.
Publicado: (2013)

Serum levels of osteoprotegerin and receptor activator of nuclear factor -κB ligand in children with early juvenile idiopathic arthritis: a 2-year prospective controlled study
por: Lien, Gunhild, et al.
Publicado: (2010)

Expression of osteoprotegerin and its ligands, RANKL and TRAIL, in rheumatoid arthritis
por: Remuzgo-Martínez, Sara, et al.
Publicado: (2016)

Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
por: Widschwendter, Martin, et al.
Publicado: (2015)

IGF-I increases markers of osteoblastic activity and reduces bone resorption via osteoprotegerin and RANK-ligand
por: Guerra-Menéndez, Lucia, et al.
Publicado: (2013)

RANK, RANKL and osteoprotegerin in bone biology and disease
por: Wright, H. L., et al.
Publicado: (2009)

Osteoprotegerin in Bone Metastases: Mathematical Solution to the Puzzle
por: Ryser, Marc D., et al.
Publicado: (2012)

Osteoprotegerin in breast cancer: beyond bone remodeling
por: Weichhaus, Michael, et al.
Publicado: (2015)

Bone Turnover Markers and Osteoprotegerin in Uncomplicated Pregnancy
por: Styczynska, Hanna, et al.
Publicado: (2009)

Effect of Breastfeeding on Serum Osteoprotegerin and Soluble Receptor Activator of Nuclear Factor-Kappa B Ligand in Full Term Neonates
por: Rafeey, Mandana, et al.
Publicado: (2013)

Reveromycin A Administration Prevents Alveolar Bone Loss in Osteoprotegerin Knockout Mice with Periodontal Disease
por: Mizuno, Manami, et al.
Publicado: (2015)

Effects of alpha-calcitonin gene-related peptide on osteoprotegerin and receptor activator of nuclear factor-κB ligand expression in MG-63 osteoblast-like cells exposed to polyethylene particles
por: Xu, Jie, et al.
Publicado: (2010)

Production of Soluble Receptor Activator of Nuclear Factor Kappa-Β Ligand and Osteoprotegerin by Apical Periodontitis Cells in Culture and Their Modulation by Cytokines
por: Duka, Miloš, et al.
Publicado: (2019)

Local Production of Osteoprotegerin by Osteoblasts Suppresses Bone Resorption
por: Cawley, Keisha M., et al.
Publicado: (2020)

Bone Alterations in Inflammatory Bowel Diseases: Role of Osteoprotegerin
por: Priadko, Kateryna, et al.
Publicado: (2022)

Effects of pamidronate disodium on the loss of osteoarthritic subchondral bone and the expression of cartilaginous and subchondral osteoprotegerin and RANKL in rabbits
por: Lv, You, et al.
Publicado: (2014)

Serum osteoprotegerin levels are related to height loss: The Tromsø Study
por: Jørgensen, Lone, et al.
Publicado: (2011)

Role of osteoprotegerin/receptor activator of nuclear factor kappa B/receptor activator of nuclear factor kappa B ligand axis in nonalcoholic fatty liver disease
por: Pacifico, Lucia, et al.
Publicado: (2018)

Roles of osteoprotegerin in endocrine and metabolic disorders through receptor activator of nuclear factor kappa-B ligand/receptor activator of nuclear factor kappa-B signaling
por: Zhang, Luodan, et al.
Publicado: (2022)

Prolactin blocks the expression of receptor activator of nuclear factor κB ligand and reduces osteoclastogenesis and bone loss in murine inflammatory arthritis
por: Ledesma-Colunga, Maria G., et al.
Publicado: (2017)

Interleukin-19 promotes bone resorption by suppressing osteoprotegerin expression in BMSCs in a lipopolysaccharide-induced bone loss mouse model
por: Dai, Zhicheng, et al.
Publicado: (2023)

Association of Serum Osteoprotegerin Levels with Bone Loss in Chronic Kidney Disease: Insights from the KNOW-CKD Study
por: Kim, Chang Seong, et al.
Publicado: (2016)

Loss of p53 in mesenchymal stem cells promotes alteration of bone remodeling through negative regulation of osteoprotegerin
por: Velletri, Tania, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vbfk2sq0hj0tnef9p1e5rqgal1